Jean Bennett
Director/Board Member bij REGENXBIO INC.
Vermogen: 63 421 $ op 31-03-2024
Actieve functies van Jean Bennett
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
REGENXBIO INC. | Director/Board Member | 01-03-2021 | - |
Independent Dir/Board Member | 01-03-2021 | - | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Director/Board Member | 01-02-2021 | - |
Founder | 01-02-2021 | - | |
Perelman School of Medicine | Corporate Officer/Principal | - | - |
Loopbaan van Jean Bennett
Eerdere bekende functies van Jean Bennett
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Founder | - | - |
SPARK THERAPEUTICS, INC. | Founder | - | - |
Gensight Biologics, Inc. | Founder | - | - |
Center For Advanced Retinal & Ocular Therapies | Director/Board Member | - | - |
Opleiding van Jean Bennett
Harvard University | Doctorate Degree |
Yale University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 11 |
Operationeel
Founder | 4 |
Director/Board Member | 3 |
Doctorate Degree | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 5 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
REGENXBIO INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Gensight Biologics, Inc. | |
Center For Advanced Retinal & Ocular Therapies | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
- Beurs
- Insiders
- Jean Bennett
- Ervaring